Please assess the completion status of the following clinical trial:

Trial Title: The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with extra-cardiac biopsy-proven AL or ATTR amyloidosis~2. Patients with a ratio of affected to unaffected free light chains \>5 or free light chain difference of \>50~Exclusion Criteria:~1. Echocardiographic evidence of cardiac amyloidosis with septal and posterior wall thickness ≥ 13mm~2. Contraindication to florbetapir or its components~3. Refusal to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- AL or TTR type amyloidosis (Type: EXPERIMENTAL): The participants will undergo F-18 florbetapir PET scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).